New drug aims to delay relapse in High-Risk blood cancer
NCT ID NCT07509151
First seen Apr 03, 2026 · Last updated May 04, 2026 · Updated 2 times
Summary
This study tests a new drug called surovatamig in people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have a high-risk genetic type (unmutated IGHV). After completing their first round of treatment, participants will either receive surovatamig or be watched closely. The goal is to see if the drug can keep the cancer from coming back longer. About 420 adults will take part in this phase 3 trial.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKAEMIA OR SMALL LYMPHOCYTIC LYMPHOMA WITH UNMUTATED IGHV are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Research Site
Adelaide, 5000, Australia
-
Research Site
Fitzroy, 3065, Australia
-
Research Site
Nedlands, 6009, Australia
-
Research Site
Calgary, Alberta, T2N 5G2, Canada
-
Research Site
Hamilton, Ontario, L8V 5C2, Canada
-
Research Site
Montreal, Quebec, H3T 1E2, Canada
-
Research Site
Istanbul, 34899, Turkey (Türkiye)
-
Research Site
Mezitli, 33200, Turkey (Türkiye)
-
Research Site
Edinburgh, EH4 2XU, United Kingdom
-
Research Site
Leeds, LS9 7TF, United Kingdom
-
Research Site
London, SE5 9RS, United Kingdom
-
Research Site
Oxford, OX3 7LE, United Kingdom
-
Research Site
Sutton, SM2 5PT, United Kingdom
Conditions
Explore the condition pages connected to this study.